Logo image of AGIO

AGIOS PHARMACEUTICALS INC (AGIO) Stock Fundamental Analysis

NASDAQ:AGIO - Nasdaq - US00847X1046 - Common Stock - Currency: USD

35.22  +1.47 (+4.36%)

After market: 35.22 0 (0%)

Fundamental Rating

5

Taking everything into account, AGIO scores 5 out of 10 in our fundamental rating. AGIO was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AGIO as it has an excellent financial health rating, but there are worries on the profitability. AGIO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year AGIO has reported negative net income.
In the past year AGIO has reported a negative cash flow from operations.
In multiple years AGIO reported negative net income over the last 5 years.
In the past 5 years AGIO always reported negative operating cash flow.
AGIO Yearly Net Income VS EBIT VS OCF VS FCFAGIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

AGIO has a better Return On Assets (40.51%) than 99.47% of its industry peers.
AGIO has a Return On Equity of 43.72%. This is amongst the best in the industry. AGIO outperforms 98.93% of its industry peers.
Industry RankSector Rank
ROA 40.51%
ROE 43.72%
ROIC N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
AGIO Yearly ROA, ROE, ROICAGIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

AGIO has a better Profit Margin (1845.92%) than 99.82% of its industry peers.
With an excellent Gross Margin value of 88.59%, AGIO belongs to the best of the industry, outperforming 91.65% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 1845.92%
GM 88.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGIO Yearly Profit, Operating, Gross MarginsAGIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

9

2. Health

2.1 Basic Checks

AGIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGIO has more shares outstanding
AGIO has less shares outstanding than it did 5 years ago.
There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AGIO Yearly Shares OutstandingAGIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AGIO Yearly Total Debt VS Total AssetsAGIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

AGIO has an Altman-Z score of 9.14. This indicates that AGIO is financially healthy and has little risk of bankruptcy at the moment.
AGIO has a Altman-Z score of 9.14. This is amongst the best in the industry. AGIO outperforms 86.86% of its industry peers.
There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.14
ROIC/WACCN/A
WACC9.44%
AGIO Yearly LT Debt VS Equity VS FCFAGIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

AGIO has a Current Ratio of 11.90. This indicates that AGIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 11.90, AGIO belongs to the top of the industry, outperforming 84.19% of the companies in the same industry.
A Quick Ratio of 11.56 indicates that AGIO has no problem at all paying its short term obligations.
AGIO has a better Quick ratio (11.56) than 83.84% of its industry peers.
Industry RankSector Rank
Current Ratio 11.9
Quick Ratio 11.56
AGIO Yearly Current Assets VS Current LiabilitesAGIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for AGIO have decreased strongly by -10.35% in the last year.
Measured over the past years, AGIO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.03% on average per year.
Looking at the last year, AGIO shows a very strong growth in Revenue. The Revenue has grown by 36.07%.
EPS 1Y (TTM)-10.35%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%16.28%
Revenue 1Y (TTM)36.07%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%51.06%

3.2 Future

Based on estimates for the next years, AGIO will show a very strong growth in Earnings Per Share. The EPS will grow by 22.87% on average per year.
Based on estimates for the next years, AGIO will show a very strong growth in Revenue. The Revenue will grow by 97.11% on average per year.
EPS Next Y-7.2%
EPS Next 2Y7.88%
EPS Next 3Y18.19%
EPS Next 5Y22.87%
Revenue Next Year128.49%
Revenue Next 2Y125.61%
Revenue Next 3Y131.17%
Revenue Next 5Y97.11%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
AGIO Yearly Revenue VS EstimatesAGIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
AGIO Yearly EPS VS EstimatesAGIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGIO Price Earnings VS Forward Price EarningsAGIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGIO Per share dataAGIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

AGIO's earnings are expected to grow with 18.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.88%
EPS Next 3Y18.19%

More info and screens

0

5. Dividend

5.1 Amount

AGIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGIOS PHARMACEUTICALS INC

NASDAQ:AGIO (2/21/2025, 8:00:22 PM)

After market: 35.22 0 (0%)

35.22

+1.47 (+4.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners105.55%
Inst Owner Change3.96%
Ins Owners0.66%
Ins Owner Change-0.08%
Market Cap2.01B
Analysts78.67
Price Target57.8 (64.11%)
Short Float %9.15%
Short Ratio5.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-148.85%
Min EPS beat(2)-314.16%
Max EPS beat(2)16.46%
EPS beat(4)2
Avg EPS beat(4)-71.83%
Min EPS beat(4)-314.16%
Max EPS beat(4)16.46%
EPS beat(8)5
Avg EPS beat(8)-32.95%
EPS beat(12)9
Avg EPS beat(12)-7.86%
EPS beat(16)11
Avg EPS beat(16)125.69%
Revenue beat(2)1
Avg Revenue beat(2)2.84%
Min Revenue beat(2)-7.11%
Max Revenue beat(2)12.79%
Revenue beat(4)1
Avg Revenue beat(4)-1.92%
Min Revenue beat(4)-9.26%
Max Revenue beat(4)12.79%
Revenue beat(8)3
Avg Revenue beat(8)-2.05%
Revenue beat(12)4
Avg Revenue beat(12)-0.13%
Revenue beat(16)4
Avg Revenue beat(16)-25.1%
PT rev (1m)-1.4%
PT rev (3m)7.53%
EPS NQ rev (1m)-0.18%
EPS NQ rev (3m)-0.18%
EPS NY rev (1m)-0.36%
EPS NY rev (3m)-0.36%
Revenue NQ rev (1m)0.59%
Revenue NQ rev (3m)0.59%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 55.03
P/FCF N/A
P/OCF N/A
P/B 1.3
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-7
EYN/A
EPS(NY)-7.5
Fwd EYN/A
FCF(TTM)-6.87
FCFYN/A
OCF(TTM)-6.84
OCFYN/A
SpS0.64
BVpS27.02
TBVpS27.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 40.51%
ROE 43.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1845.92%
GM 88.59%
FCFM N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.81%
Cap/Sales 4.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.9
Quick Ratio 11.56
Altman-Z 9.14
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)33.97%
Cap/Depr(5y)62.68%
Cap/Sales(3y)14.2%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.35%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%16.28%
EPS Next Y-7.2%
EPS Next 2Y7.88%
EPS Next 3Y18.19%
EPS Next 5Y22.87%
Revenue 1Y (TTM)36.07%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%51.06%
Revenue Next Year128.49%
Revenue Next 2Y125.61%
Revenue Next 3Y131.17%
Revenue Next 5Y97.11%
EBIT growth 1Y-8.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.68%
OCF growth 3YN/A
OCF growth 5YN/A